Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands
- 1 February 2001
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 20 (2) , 160-163
- https://doi.org/10.1097/00006454-200102000-00008
Abstract
To calculate both medical consumption and socioeconomic effects related to hospitalization for respiratory syncytial virus (RSV) infection in the Netherlands. During the winter seasons of 1998 to 2000, parents of all patients hospitalized for RSV in three secondary care hospitals were asked to fill out questionnaires focusing on the 2 weeks before hospitalization, the period in hospital and the 2 weeks after discharge. The questions concerned workdays lost, level of education and current profession, extra childcare needed, consultation by the family physician and drugs prescribed and costs of travelling. Seventy-three children were hospitalized. Median age was 79 days (range, 9 to 537 days), and median weight was 5295 g (range, 3130 to 10 600 g). Three children were born preterm. Parents had 2 (range, 0 to 6) telephone contacts with the family doctor; the child was seen 2 (range, 0 to 4) times before hospitalization. Parents lost 0.5 workday before hospitalization. Duration of hospitalization was 5 days median (range, 1 to 12 days). Parents lost 1.5 (range, 0 to 9) workdays during hospitalization and drove 118 (range, 6 to 550) miles to visit their child. In the period after discharge expenses were negligible. Calculation of all parameters into currency resulted in a total amount of $2200 per child hospitalized for RSV. Workdays lost, costs for travelling and consultation of family doctors resulted in $295 per child. RSV infections necessitating hospitalization in a secondary care hospital have remarkable effects on parental expenses, parental absence from work and medical consumption. On top of the hospital-related costs 15% should be added for parental expenses and socioeconomic costs.Keywords
This publication has 7 references indexed in Scilit:
- Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and costThe Pediatric Infectious Disease Journal, 2000
- Respiratory syncytial virus infectionThe Lancet, 1999
- Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm InfantsPublished by American Academy of Pediatrics (AAP) ,1999
- Epidemiology of respiratory syncytial virus infection requiring hospitalization in East DenmarkThe Pediatric Infectious Disease Journal, 1998
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Economic evaluation of respiratory syncytial virus infection in Canadian children: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) studyThe Journal of Pediatrics, 1997